To Study the Regulatory Guidelines for API of Ibuprofen: A Review
DOI:
https://doi.org/10.22270/ajprd.v12i1.1356Abstract
The registration structure of pharmaceutical outcomes is governed by pharmaceutical medication regulatory affairs. It has a broad scope that encompasses all aspects of documentation and marketing in a legitimate format. In our country, the pharmaceutical business is one of the most coordinated industries. Regulatory affairs experts require a current market overview in order to connect pharmaceutical companies with international regulatory bodies. Regulatory issues RA is a career that overlaps a number of industries, including pharmaceuticals, medical devices, and biotechnology. Within the pharmaceutical sector, RA has a specific connotation. DRA is a dynamic field that encompasses both scientific and legal aspects of drug development. DRA professionals are dedicated individuals who take pride in their contribution to improving humanity’s health and quality of life. The scope of RA as a profession is much more than the registration of outcomes. They provide strategic and practical advice to businesses at a high level. Their small continues through preparation, marketing, and post-marketing. Professionals from RA help the organisation avoid problems caused by sloppy records, incorrect scientific reasoning, or poor data presentation. The claims that can be made for the product on labelling or in advertising are usually restricted in most outcomes areas where regulatory limitations are imposed.
Downloads
References
Introduction to pharma regulatory affairs [online] 2016. Available from https://www.slideshare.net/GIBTIndia/introduction-to-pharma-regulatory-affairs
Suryakanta Swain , Responsibility of Regulatory Affairs in Pharmaceutical Industry , Swain , Pharmaceut Reg Affairs 2012 , 1:1 DOI: 10.4172/2167-7689.1000e104
Mr. Rajesh Dumpala , Mr. Chirag Patil , An overview of Regulatory Affairs in Pharmaceutical Industry , International journal of university pharmacy and bio sciences , July-August 2020 , ISSN: 2319-8141.
Introduction to Regulatory Affairs, prepared by Naila Kanwal [online] 2015. Available from https://www.slideshare.net/NailaKanwal/regulatory-affairs-55362084
Regulatory Affairs Profession , prepared by Ms. Angha Maharao [online] 2014 Available from https://www.slideshare.net/InstituteofPharmaceu/regulatory-affairs-profession-34479113
Firoz Roshan , ph.D. , Role of Regulatory Affairs in Clinical Drug Development, PPD Scandinavia AB , Stockholm , Sweden.
Y. Sri Harsha, V.Sharmila Reddy, D. Mary, D.Nagarjunareddy, M.V.Nagabhusanam, Brahmaiah Bonthagarala , Role of Regulatory Affairs in a Pharmaceutical Industry , 27/04/2017 , ISSN:2277-8713
Sumit Kumar, Rishabh Panwar, Upendra Singh, Regulatory Affairs in the Pharmacy Curriculum, Oct. 2013.
Sharma S, Bodla R.B., Shweta S, Pathak D.P. , Pharmaceutical Quality Management System , International Journal of Drug Regulatory Affairs; 2014, 2(3), 67-78 , ISSN: 2321 – 6794
Keshari Roshan , Jha Aayush , Role of Regulatory Affairs in Pharmaceutical Company , Jan-2018 , ISSN No 2277-8160
Tarun Kumar Reddy, Naveen Kumar Reddy, Significance of Pharmaceutical Regulatory Bodies , E-ISSN: 2347-7881
The American Society of Health-System Pharmacists. Archived from the original on 9 September 2017. Retrieved 12 October 2016.
Beaver WT (April 2003). "Review of the analgesic efficacy of ibuprofen". International Journal of Clinical Practice. Supplement (135): 13–7.
Kyselovič J, Koscova E, Lampert A, Weiser T (June 2020). "A Randomized, DoubleBlind, Placebo-Controlled Trial of Ibuprofen Lysinate in Comparison to Ibuprofen
Acid for Acute Postoperative Dental Pain". Pain and Therapy. Doi:10.1007/s40122019-00148-1. PMC 7203382. PMID 31912434.
Fanos V, Antonucci R, Zaffanello M (2010). "Ibuprofen and acute kidney injury in the newborn". The Turkish Journal of Pediatrics.
Klaus Florey, Edited by Harry G. Brittain, Analytical Profiles of Drug Substance and Excipients, volume 27, Pg No. 265-300.
NIST Chemistry Web Book [online] , https://webbook.nist.gov/cgi/cbook.cgi?ID=15687-27-1&Units=SI&cMS=on
United States Pharmacopoeia NF , Vol-2 , Pg. no. 2067-2068
British Pharmacopoeia , Vol-1 , Pg. no. 1048-1050
Indian Pharmacopoeia, Vol-2, Pg. no. 2261-2263
Published
How to Cite
Issue
Section
Copyright (c) 2024 Shraddha V. Jadhav, Nikam A.S., Gunjal S.B.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.